Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group

Simple item page
dc.contributor.authorGungorduk K.
dc.contributor.authorErtas I.E.
dc.contributor.authorSahbaz A.
dc.contributor.authorOzvural S.
dc.contributor.authorSarica Y.
dc.contributor.authorOzdemir A.
dc.contributor.authorSayhan S.
dc.contributor.authorGokcu M.
dc.contributor.authorYilmaz B.
dc.contributor.authorSanci M.
dc.contributor.authorInan S.
dc.contributor.authorHarma M.
dc.contributor.authorYildirim Y.
dc.date.accessioned2024-07-22T08:17:01Z
dc.date.available2024-07-22T08:17:01Z
dc.date.issued2014
dc.description.abstractObjective: To analyze the expression patterns of extracellular signal-regulated kinase (ERK1/2) and phosphorylated (p)-AKT in the tissues of non-pathologic endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer using indirect immunohistochemistry, and also to investigate the effect of ERK1/2 and p-AKT expression patterns on prognosis in endometrioid adenocancer. Study design: Immunolocalization of ERK1/2 and p-AKT was examined in six different types of endometrial tissues: proliferative endometrium (PE; n = 10, 11.2%), secretuar endometrium (SE; n = 10, 11.2%), simple hyperplasia (SH; n = 15, 16.9%), complex hyperplasia (CH; n = 3, 3.4%) and atypical complex hyperplasia (ACH; n = 10, 11.2%), which were obtained from endometrial biopsies, curettage materials, and hysterectomy specimens and classified as the benign group; and both early stage endometrioid (n = 21, 23.6%) and advanced stage endometrioid adenocancer (AC; n = 20, 22.5%), which were obtained from complete surgical staging materials and classified as the malignant group. All specimens were fixed in 10% formalin and processed using routine paraffin protocols. Immunostaining intensities were evaluated as negative or weak (assigned as low expression) and moderate or strong (assigned as high expression). Results: In the malignant group, 23 of 41 patients (56.1%) had high ERK1/2 and p-AKT expression, whereas only three of 48 patients in the benign group (6.3%) had high ERK1/2 and p-AKT expression (P < 0.0001 and P < 0.0001, respectively). p-AKT expression was significantly higher in women with positive lymph nodes (OR 9.0; 95% CI: 1.2-100.0; P = 0.03). Higher expression of p-AKT was significantly associated with poor progression-free survival (PFS) and overall survival (OS). In contrast, ERK1/2 expression was not associated with PFS or OS.Conclusions ERK1/2 and p-AKT can be useful in the differential diagnosis of benign vs. malignant endometrial lesions, as well as early vs. advanced stage endometrioid endometrial adenocancer. Additionally, higher p-AKT expression could be used as a marker of poor prognosis in the management of patients with endometrioid endometrial adenocancer. © 2014 Elsevier Ireland Ltd. All rights reserved.
dc.identifier.DOI-ID10.1016/j.ejogrb.2014.05.040
dc.identifier.issn03012115
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/16950
dc.language.isoEnglish
dc.publisherElsevier Ireland Ltd
dc.subjectAdult
dc.subjectAged
dc.subjectCarcinoma, Endometrioid
dc.subjectDisease-Free Survival
dc.subjectEndometrial Hyperplasia
dc.subjectEndometrial Neoplasms
dc.subjectEndometrium
dc.subjectExtracellular Signal-Regulated MAP Kinases
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectImmunohistochemistry
dc.subjectMiddle Aged
dc.subjectPhosphorylation
dc.subjectPrognosis
dc.subjectProto-Oncogene Proteins c-akt
dc.subjectformaldehyde
dc.subjectmitogen activated protein kinase 1
dc.subjectmitogen activated protein kinase 3
dc.subjectparaffin
dc.subjectprotein kinase B
dc.subjectmitogen activated protein kinase
dc.subjectprotein kinase B
dc.subjectadult
dc.subjectadvanced cancer
dc.subjectadvanced stage endometrioid endometrial adenocancer
dc.subjectarticle
dc.subjectcancer prognosis
dc.subjectcancer staging
dc.subjectcancer survival
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectearly cancer
dc.subjectearly stage endometrioid endometrial adenocancer
dc.subjectendometrioid carcinoma
dc.subjectendometrioid endometrial adenocancer
dc.subjectendometrium
dc.subjectendometrium biopsy
dc.subjectendometrium carcinoma
dc.subjectendometrium hyperplasia
dc.subjectenzyme phosphorylation
dc.subjectfemale
dc.subjectfollow up
dc.subjecthuman
dc.subjecthuman tissue
dc.subjecthysterectomy
dc.subjectimmunohistochemistry
dc.subjectimmunolocalization
dc.subjectlymph node
dc.subjectlymph node metastasis
dc.subjectlymph vessel metastasis
dc.subjectmenopause
dc.subjectmetastasis
dc.subjectmiddle aged
dc.subjectmyometrial invasion
dc.subjectoverall survival
dc.subjectpriority journal
dc.subjectprogression free survival
dc.subjectprotein expression
dc.subjecttumor volume
dc.subjectadvanced cancer
dc.subjectArticle
dc.subjectcancer classification
dc.subjectcancer diagnosis
dc.subjectcancer prognosis
dc.subjectcancer surgery
dc.subjectcurettage
dc.subjectdifferential diagnosis
dc.subjectendometrioid carcinoma
dc.subjectendometrium
dc.subjectendometrium carcinoma
dc.subjectendometrium hyperplasia
dc.subjectaged
dc.subjectdisease free survival
dc.subjectendometrioid carcinoma
dc.subjectendometrium hyperplasia
dc.subjectendometrium tumor
dc.subjectmetabolism
dc.subjectpathology
dc.subjectphosphorylation
dc.subjectprognosis
dc.titleImmunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group
dc.typeArticle

Files

Collections

Scopus Koleksiyonu